Recent News

  • ACR 2026 Day 3 Report

    Jack Cush, MD
    meeting.audience.3_0.jpg

    Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:

    Read Article
Dr. John Cush Tweet
@RheumNow
Weight Loss and Arthritis: A focus on patient-reported outcomes Obesity is associated with poorer physical function and treatment response in rheumatoid arthritis (RA). The ACR guideline on exercise, rehabilitation and diet supports discussing healthy body weight as part of https://t.co/GynYYRqC4T
anita Tweet
@docdhanrajani
@RheumNow abstract 2480. Can high-fidelity simulation help bridge gaps in pediatric rheumatology education? Pilot modules boosted learner confidence in core competencies. A promising approach to improve disease recognition and timely referrals amid workforce shortages! #ACR26
anita Tweet
@docdhanrajani
@RheumNow Abstract 2489. Important finding in JSpA! Children can have significant spinal inflammation WITHOUT sacroiliitis, potentially missing current classification criteria. High clinical suspicion and imaging beyond the SI joints are key to early diagnosis. #ACR2026
Adela Castro Tweet
@AdelaCastro222
Lip biopsy for Sjogren's disease diagnosis? Great debate at #ACR26 @RheumNow
Adela Castro Tweet
@AdelaCastro222
ACR 2026 guidelines for management of OA 1. Self management programs: educate pts on the disease and involve them in their care. 2. PT/OT-Key! 3. Mobility aids if limited walking. 4. Exercise! all of them recommended. 5. Wt loss if hip/knee OA and overwt or obese 6. Topical https://t.co/JnbNaZ3CSw
Bella Mehta Tweet
@bella_mehta
Pain outcomes require more than analgesics. #ACR26 Abs#1555: 196 pts with FM followed for 12 mos, catastrophizing and insomnia independently tracked with greater pain and symptom burden regardless of rehab pathway. Assess without stigmatizing. @RheumNow
Janet Pope Tweet
@Janetbirdope
Is it ok to re-analyze a #negative #RCT in #Raynaud’s Likely yes to learn how to study Ph3 or abandon drug Abst#2907 -neg RCT in #RP w #cilnidipine a marketed anti hypertensive Some ‘trends’ Studied to inform Future RCT on dose, outcome measures #ACR26 @RheumNow @ACRheum https://t.co/3AoiZ3juk4
Janet Pope Tweet
@Janetbirdope
#H2H #RCTs in #PsA, #PsO Of #IL17i vs #IL23i /IL12/23i For #PsO IL23i>IL17i #guselkumab >secukinumab #Secukinumab>#ustekinumab for #HAQ DI in PsA #PsA #bimekizumab>#risankizumab depends on what you want as outcome #psoriasis v #psoriatic #arthritis #ACR26 @RheumNow #2804 https://t.co/kOQiC5O68Y
Mrinalini Dey Tweet
@DrMiniDey
Do we have a marker for RA-ILD severity? Higher MMP7 was assoc with greater CT involvement and lower DLCO; not FVC or respiratory symptom scores. HRCT & DLCO also more sensitive indicators of RAILD progression and severity than FVC and respiratory PROs #2886 @Rheumnow #ACR26
Dr. John Cush Tweet
@RheumNow
RheumNow’s expanded coverage of #ACR26 annual meeting is sponsored by Eli Lilly and Company. All content is independently selected by RheumNow and its faculty.

Video

Podcasts

  • ACR 2026 RheumNow Day 3 Recap
  • ACR 2026 Daily Podcasts - Day2c
  • ACR 2026 Daily Podcasts - Day2b
  • ACR 2026 Daily Podcasts - Day2a
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie November RX Update
In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions
Read Post
×